Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USDA grants

This article was originally published in The Tan Sheet

Executive Summary

The Department of Agriculture seeks comments on proposed revisions to the uniform application package for the Food and Nutrition Service's discretionary grant programs open to businesses as well as non-profit groups. In an Aug. 20 Federal Register 1notice, USDA says the revisions will continue the authority for the uniform grant application package and update the estimate of time applicants need to complete the forms. The package can be used for all FNS' discretionary grant programs to collect information from applicants needed to evaluate and rank applicants and protect the integrity of the selection process. The proposed information collection covered by the notice is related to requirements for program narrative statements. The affected entities are state and local governments, Indian tribal organizations, institutions of higher education and hospitals as well as non- and for-profit organizations. The deadline for comments is Oct. 20

You may also be interested in...



FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Coronavirus Update: Pfizer Urged To Delay Vaccine Submission

A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel